ArticleJournal of carcinogenesis2011
Mouse models of estrogen receptor-positive breast cancer.
Article in Journal of carcinogenesis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer.NPJ breast cancer · 2026Article
- Patient-derived response estimates from zero-passage organoids of luminal breast cancer.Breast cancer research : BCR · 2024Article
- Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.Communications biology · 2024Article
- Patient-derived response estimates from zero-passage organoids of luminal breast cancer.bioRxiv : the preprint server for biology · 2024Article
- Ecdysoneless Overexpression Drives Mammary Tumorigenesis through Upregulation of C-MYC and Glucose Metabolism.Molecular cancer research : MCR · 2022Article
- Experimental models of endocrine responsive breast cancer: strengths, limitations, and use.Cancer drug resistance (Alhambra, Calif.) · 2021Article
- Prognostic Significance of Inflammatory Biomarkers in Patients with Breast Cancer Skeletal Metastases.Cancer management and research · 2020Article
- Transcriptional regulation of normal human mammary cell heterogeneity and its perturbation in breast cancer.The EMBO journal · 2019Review
- Mouse ER+/PIK3CAOncogene · 2019Article
- DMBA promotes ErbB2‑mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability.Oncology reports · 2018Article
- Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.Oncotarget · 2018Article
- Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model.Scientific reports · 2018Article
- Emerging Roles of Estrogen-Related Receptors in the Brain: Potential Interactions with Estrogen Signaling.International journal of molecular sciences · 2018Review
- Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERαCancer research · 2018Article
- SRC IncreasesMolecular and cellular biology · 2018Article
- Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.Oncotarget · 2017Article
- Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.Breast cancer research : BCR · 2017Article
- Role of dietary bioactive natural products in estrogen receptor-positive breast cancer.Seminars in cancer biology · 2016Review
- Induction of apoptosis and downregulation of ERα in DMBA-induced mammary gland tumors in Sprague-Dawley rats by synthetic 3,5-disubstituted isoxazole derivatives.Molecular and cellular biochemistry · 2016Article
- Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER⁺ Breast Cancer.Cancer cell · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Breast cancer is the most frequent malignancy and second leading cause of cancer-related deaths among women. Despite advances in genetic and biochemical analyses, the incidence of breast cancer and its associated mortality remain very high. About 60 - 70% of breast cancers are Estrogen Receptor alpha (ER-α) positive and are dependent on estrogen for growth. Selective estrogen receptor modulators (SERMs) have therefore provided an effective targeted therapy to treat ER-α positive breast cancer patients. Unfortunately, development of resistance to endocrine therapy is frequent and leads to cancer recurrence. Our understanding of molecular mechanisms involved in the development of ER-α positive tumors and their resistance to ER antagonists is currently limited due to lack of experimental models of ER-α positive breast cancer. In most mouse models of breast cancer, the tumors that form are typically ER-negative and independent of estrogen for their growth. However, in recent years more attention has been given to develop mouse models that develop different subtypes of breast cancers, including ER-positive tumors. In this review, we discuss the currently available mouse models that develop ER-α positive mammary tumors and their potential use to elucidate the molecular mechanisms of ER-α positive breast cancer development and endocrine resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.